Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
In a 2023 Gallup survey, 62% of American adults under 35 said they drink alcohol, down from 72% twenty years earlier.
The odds of an increase in regulation of the massive, and growing, sports-betting industry may be shifting.
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.